Robert Evans

Robert Evans

Robert Evans

Prior to ALI, Robert Evans led drug development efforts from discovery to post-marketing at several biotech and pharmaceutical firms, most recently as vice president and head of clinical science for Glenmark Pharmaceuticals. Mr. Evans has headed efforts resulting in the successful launches of new treatments for conditions including hepatitis, rheumatoid arthritis, psoriatic arthritis, psoriasis, and Crohn’s disease, among others. 

As an ALI Fellow, he hopes to address the increasing costs of prescription drugs through the development of a nonprofit distributional system for generic drugs.

 

Person Role